US pharma major Eli Lilly (NYSE: LLY) says that Taltz (ixekizumab) has been recommended by the National Institute for Health and Care Excellence (NICE) for use as a treatment option within the NHS in England, Wales and Northern Ireland for adults with severe plaque psoriasis who have responded inadequately to standard systemic therapies.
The NICE, the medicines cost-effectiveness watch dog, published its final Technology Appraisal Guidance (TAG) on the use of ixekizumab today.
Ixekizumab is recommended as an option for treating plaque psoriasis in adults, only if:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze